SCHEMBL4764168

SCHEMBL4764168

CCCCOc1ccccc1C1CCC[N]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 2/20 0.47
HTR1B P28222 2/20 0.47
CYP2C9 P11712 3/20 0.44
CYP2C19 P33261 3/20 0.44
CYP1A2 P05177 2/20 0.44
LMNA P02545 3/20 0.42
CYP3A4 P08684 1/20 0.42
TP53 P04637 4/20 0.41
MAPT P10636 1/20 0.41
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
TSHR P16473 3/20 0.41
GAA P10253 2/20 0.41
HTT P42858 2/20 0.41
POLB P06746 1/20 0.40
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 2/20 0.40
GLA P06280 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723202 0.96 HTR1D (0.49) HTR1DHTR1BCYP2C9CYP2C19CYP1A2
SCHEMBL4721419 0.93 HTR2C (0.48) HTR1DHTR1BCYP2C9CYP2C19CYP1A2
SCHEMBL4720767 0.89 HTR1D (0.48) HTR1DHTR1BCYP2C9CYP2C19CYP1A2
SCHEMBL4724844 0.87 HTR2A (0.46) HTR1DHTR1BLMNAMAPTHTR2C
SCHEMBL4720346 0.82 ALDH1A1 (0.44) HTR1DHTR1BLMNAMAPTHTR2C
SCHEMBL4723022 0.80 TP53 (0.41) HTR1DHTR1BCYP2C9CYP2C19CYP1A2
SCHEMBL3165666 0.79 HTR2C (0.47) HTR2CHTR2BTSHRL3MBTL1KMT2A
SCHEMBL4721571 0.74 HTR2C (0.46) HTR2CHTR2BALDH1A1L3MBTL1KMT2A
SCHEMBL4970290 0.74 HTR2C (0.46) HTR2CHTR2BALDH1A1L3MBTL1KMT2A
SCHEMBL4723063 0.73 TP53 (0.43) HTR1DHTR1BCYP2C9CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 HTR1D 94/4885HTR1B 111/4885CYP2C9 303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.